Related references
Note: Only part of the references are listed.Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).
Giovanni Scambia et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
Sandro Pignata et al.
ONCOLOGIST (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2020)
Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO 2/ENGOT Ov-21 trial
J-S. Frenel et al.
ANNALS OF ONCOLOGY (2020)
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
Nicoletta Colombo et al.
BRITISH JOURNAL OF CANCER (2019)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
M. K. Wilson et al.
ANNALS OF ONCOLOGY (2017)
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?
Federica Tomao et al.
CANCER (2017)
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
D. Lorusso et al.
ANNALS OF ONCOLOGY (2016)
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study
B. J. Monk et al.
ANNALS OF ONCOLOGY (2015)
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
B. Colmegna et al.
BRITISH JOURNAL OF CANCER (2015)
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin
Andres Poveda et al.
CANCER TREATMENT REVIEWS (2014)
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
L. Gladieff et al.
ANNALS OF ONCOLOGY (2012)
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer
Angeles Alvarez Secord et al.
CANCER (2012)
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
A. Poveda et al.
ANNALS OF ONCOLOGY (2011)
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies
Ignace Vergote et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
GJS Rustin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer
E Greimel et al.
EUROPEAN JOURNAL OF CANCER (2003)
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
G Damia et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
